A R T I C L E S
Hu et al.
dinitro (380 nm), 5-nitro-6-chloro (380 nm), 5-nitro (380 nm), 5-cyano
(324 nm), 6-nitro (404 nm), 5,6-dichloro (342 nm), 6-chloro (329 nm),
5-chloro (339 nm), 5-fluoro (338 nm), and unsubstituted (325 nm).
Extinction coefficients were measured for each compound under the
reaction conditions. The second-order rate constants for the acetate and
butylamine-dependent reactions were determined in water or MeCN
at 20 °C. Pseudo-first-order rate constants were plotted against acetate
or butylamine concentration, and the slope of these plots gave the
second-order rate constant for the base-catalyzed reaction. The reactions
with 34E4 and BSA were performed in 40 mM phosphate, 100 mM
NaCl, pH 7.4 and 20 °C. Initial velocities were calculated by standard
linear-regression analysis using the initial linear portion of absorbance
vs time plots and were corrected for background activity. The kcat and
between the catalytic group and the transition state plus an
elaborate active site made of polar and nonpolar groups, which
provides favorable interactions with the transition state including
electrostatics, solvation and other factors.34 The most important
feature for catalysis is the assembly of catalytic functionality,
here the basic site, with appropriate orientation and reactivity.
Of course catalysts that accidentally have an appropriate
environment do exist, such as albumins in this case.
Catalytic antibodies represent a successful effort to biological
catalyst design for nonbiological reactions. The problems in such
design and execution are known5 to be difficult but not
insoluble.36,37 A remaining challenge is how to use the program-
mable nature of the antibody pocket along with medium effects
to act in concert with other active site parameters. Careful design
by increasing the strength of the catalytic base through desol-
vation and by providing specific stabilizing interactions with
the leaving group such as forming hydrogen bonds with
phenoxide, should lead to better catalysts for such a solvent
sensitive reaction.38
Km values were calculated by fitting the kinetic data to the Michaelis-
Menten equation using the program KaleidaGraph. Two percent
acetonitrile was used to dissolve the substrate for all reactions in aqueous
medium. Crystallized BSA, treated to remove bound lipids, was
purchased from Sigma and used without further purification; 34E4 was
isolated and purified as previously described.
Cloning of the Antibody Genes. Poly (A)+ mRNA was isolated
from the hybridoma producing antibody 34E4.2 A cDNA library was
constructed with the Great Lengths cDNA synthesis kit (Clontech).
The VL and VH genes were cloned using the polymerase chain reaction
with the following primers: VL sense, GTACATTTGCTCTTCGGT-
TCACAGGCTGTTGTGACTCAGGAA (the Sac I restriction site is
in italics); VL anti-sense, ATGAGTTTTTGTTCTGCGGCCGCCT-
TGGGCTGACCTAGGACAGT (Not I); VH sense AGGTCCAGCT-
GCTCGAGTCTGG (Xho I); VH anti-sense GTTCTGACTAGT-
GGGCACTCTGGGCTC (Spe I). The amplified fragments were puri-
fied, cloned into appropriate sites in the vector p4xH-M1342 and
sequenced. The resulting expression plasmid, p4xH-34E4, allows
production of 34E4 as a chimeric murine-human Fab fragment in which
the VL and VH segments of the catalytic antibody are fused to human
Cκ and gamma CH1 regions, respectively.42
Experimental Section
Synthesis of Substituted Benzisoxazoles. Unsubstituted benz-
isoxazole and the 5-nitro-, 6-nitro-, 5,7-dinitro-, 5-chloro-, and 6-chloro-
substituted derivatives were prepared according to the literature.1a,39
4-Cyano- and 4-fluorosalicylaldehyde were prepared from the corre-
sponding phenols by a Duff reaction;40 4,5-dichlorosalicylaldehyde was
prepared by a Reimer-Tiemann reaction.41 The substituted salicyl-
aldehydes were converted to benzisoxazoles by a standard literature
procedure.39b
5-Cyanobenzisoxazole. 1H NMR (300 MHz, CDCl3) δ 7.76 (q, 1H),
7.84 (q, 1H), 8.16 (d, 1H), 8.83 (d, 1 H). MS FABM+ 145 (M++H+).
mp 245 °C (decomp.).
5,6-Dichlorobenzisoxazole. 1H NMR (300 MHz, CDCl3) δ 7.80 (d,
1H), 7.85 (s, 1H), 8.68 (d, 1H). MS FABM+ 187/189 (M++H+), 210/
212 (M++Na+). mp 92 °C (sub.).
The antibody sequences for the variable segments of 34E4 are given
in Chart 1.
Construction of a Homology Model. A search of the structure
database identified antibodies HC19 (1gig.pdb)43 and J539 (2fbj.pdb)44
as having the highest sequence similarity to the 34E4 VL and VH
domains, respectively. Because HC19 and 34E4 have CDR H3 loops
that are the same length and that possess reasonable sequence similarity
(28.6%), modeling of the VL-VH interface45 is facilitated. A least-
squares fit of the VH domains of HC19 and J539, minus the CDR H3
loop, allowed overlay of the two molecules with a rmsd. of 1.40 Å for
all CR atoms except those of the CDR L1 (residues L24 to L34) and
H3 (residues H95 to H102). In this overlay, the VH domains of the
two antibodies were superimposed with rmsd. of 0.88 Å for all non-
CDR H3 CR atoms, whereas the VL domains were overlaid with rmsd.
of 1.37 Å for all non-CDR L1 CR atoms. In particular, the residues
near the VL/VH interface from the two molecules, namely residues L42-
L46, L94-L100, H43-H50, H58-H61, and H103-H105 (27 residues in
total), coincided with each other with rmsd. of 0.87 Å for all CR atoms.
Accordingly, visual inspection of the interface between the HC19 VL
and J539 VH domains revealed that no significant steric interference
was introduced by the way the two domains were put together. After
5-Fluorobenzisoxazole. 1H NMR (300 MHz, CDCl3) δ 7.32 (q, 1H),
7.38 (q, 1H), 7.59 (q, 1H), 8.7 (d, 1 H). MS FABM+ 139 (M++H+).
mp 68 °C (sub.).
5,6-Dinitrobenzisoxazole. 6-Nitrobenzisoxazole (200 mg) was dis-
solved in ice-cooled cH2SO4 (1.6 mL). Fuming nitric acid (200 µl)
was added dropwise, and the reaction mixture was heated at 80 °C for
30 min. The starting material was completely consumed. The reaction
mixture was poured onto ice and then extracted immediately with
methylene chloride. The organic layer was dried and purified by silica
gel chromatography using methylenechloride as eluent to give 142 mg
1
of the desired product in 56% yield. H NMR (300 MHz, CDCl3) δ
8.17 (q, 1H), 8.52 (d, 1H), 9.15 (d, 1H). MS FABM+ 210 (M++H+).
mp 112 °C.
5-Nitro-6-chlorobenzisoxazole. 6-Chlorobenzisoxazole was nitrated
at the 5-position by the same method used to prepare 5,6-dinitrobenz-
1
isoxazole in 62% yield. H NMR (300 MHz, CDCl3) δ 7.88 (d, 1H),
8.36 (d, 1H), 8.86 (d, 1H). MS FABM+ 198/200 (M++H+). mp 106
°C.
Kinetic Analyses. All kinetic experiments were performed at 20
°C. Fast reactions were measured by stopped flow techniques. The
reactions were initiated by adding the benzisoxazole substrate to the
reaction mixture and product formation was monitored spectrophoto-
metrically at the following wavelengths: 5,7-dinitro (352 nm), 5,6-
(39) (a) Kemp, D. S.; Woodward R. B. Tetrahedron 1965, 21, 3019-3035. (b)
Casey, M. L.; Kemp, D. S.; Paul, K. G.; Cox, D. D. J. Org. Chem. 1973,
38, 2294-2301.
(40) Suzuki, Y.; Takahashi, H. Chem. Pharm. Bull. 1983, 31, 1751-1753.
(41) Postmus, C.; Kaye, I. A.; Craig, C. A.; Matthews, R. S. J. Org. Chem.
1964, 29, 2693-2698.
(42) Ulrich, H. D., Patten, P. A., Yang, P. L., Romesberg, F. E., & Schultz, P.
G. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 11 907-11 911.
(43) Bizebard, T.; Daniels, R.; Kahn, R.; Golinellipimpaneau, B.; Skehel, J. J.;
Knossow, M. Acta Crystallog. 1994, D50, 768-777.
(44) Suh, S. W.; Bhat, T. N.; Navia, M. A.; Cohen, G. H.; Rao, D. N.; Rudikoff,
S.; Davies, D. R. Proteins: Struct. Funct. Genet. 1986, 1, 74-80.
(45) Stanfield, R. L.; Takimoto-Kamimura, M., Rini, J. M.; Profy, A. T.; Wilson,
I. A. Structure 1993, 1, 83-93.
(34) Houk, K. N.; Leach. A. G.; Kim, S. P.; Zhang, X. Angew Chem., Int. Ed.
2003, 42, 4872-4897.
(35) Zhang, X.; Houk, K. N., submitted for publication.
(36) Tantillo, D. J.; Houk, K. N. J. Org. Chem. 1999, 64, 3066-3076.
(37) Barbany, M.; Gutierrez-de-Teran, H.; Sanz, F.; Villa-Freixa, J.; Warshel,
A. ChemBioChem 2003, 4, 277-285.
(38) Parker, A. J. Chem. ReV. 1969, 69, 1-32.
9
8204 J. AM. CHEM. SOC. VOL. 126, NO. 26, 2004